acetylcholine receptor achr antagonist pipeline insight

DelveInsight’s, “Acetylcholine Receptor (AChR) Antagonist - Pipeline Insight, 2025,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Acetylcholine Receptor (AChR) Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

• Global coverage

Acetylcholine Receptor (AChR) Antagonist Understanding

Acetylcholine Receptor (AChR) Antagonist: Overview

Acetylcholine receptor (AChR) has long been known through pharmacological and electrophysiological studies as an operational entity with which acetylcholine interacts to cause a change in the ion permeability of excitable membranes. Muscarinic receptor Antagonist (MRAs) function by competitively blocking the cholinergic response manifested by acetylcholine (ACh) binding muscarinic receptors on exocrine glandular cells, cardiac muscle cells, and smooth muscle cells. Therefore, MRAs are heavily involved with the parasympathetic nervous system and act on different types of muscarinic receptors resulting in a wide array of clinical indications. Current literature suggests involvement of nicotinic acetylcholine receptors (nAChRs) in major depression.

 

"Acetylcholine Receptor (AChR) Antagonist - Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acetylcholine Receptor (AChR) Antagonist pipeline landscape is provided which includes the disease overview and Acetylcholine Receptor (AChR) Antagonist treatment guidelines. The assessment part of the report embraces, in depth Acetylcholine Receptor (AChR) Antagonist commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acetylcholine Receptor (AChR) Antagonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acetylcholine Receptor (AChR) Antagonist R&D. The therapies under development are focused on novel approaches to treat/improve Acetylcholine Receptor (AChR) Antagonist.

Acetylcholine Receptor (AChR) Antagonist Emerging Drugs Chapters

This segment of the Acetylcholine Receptor (AChR) Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Acetylcholine Receptor (AChR) Antagonist Emerging Drugs

 

AXS-05: Axsome Therapeutics

AXS-05 (dextromethorphan-bupropion) is a novel, oral, patent-protected, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of major depressive disorder and other central nervous system (CNS) disorders.The dextromethorphan component of AXS-05 is an antagonist of the NMDA receptor, an ionotropic glutamate receptor, and a sigma-1 receptor agonist. The bupropion component of AXS-05 serves primarily to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor.

AXS-05 has received Breakthrough Therapy designation from the FDA for both major depressive disorder and Alzheimer’s disease agitation. In April 2021, Axsome Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for AXS-05 for the treatment of major depressive disorder (MDD), and has granted the application Priority Review.

 

KarXT: Karuna Therapeutics

KarXT, selectively activates muscarinic acetylcholine receptors in the brain to unlock the therapeutic potential of xanomeline, which previously demonstrated significant benefits in Phase II studies in schizophrenia and Alzheimer’s. KarXT is a combination of Xanomeline, a muscarinic agonist and Trospium Chloride, a muscarinic antagonist. It is currently in Phase III stage of development for the treatment of Schizophrenia.

Further product details are provided in the report……..

Acetylcholine Receptor (AChR) Antagonist: Therapeutic Assessment

This segment of the report provides insights about the different Acetylcholine Receptor (AChR) Antagonist drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Acetylcholine Receptor (AChR) Antagonist

There are approx. 30+ key companies which are developing the therapies for Acetylcholine Receptor (AChR) Antagonist. The companies which have their Acetylcholine Receptor (AChR) Antagonist drug candidates in the most advanced stage, i.e. Pre-registration include, Axsome Therapeutics.

Phases

DelveInsight’s report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Acetylcholine Receptor (AChR) Antagonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

 

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acetylcholine Receptor (AChR) Antagonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acetylcholine Receptor (AChR) Antagonist therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acetylcholine Receptor (AChR) Antagonist drugs.

Acetylcholine Receptor (AChR) Antagonist Report Insights

• Acetylcholine Receptor (AChR) Antagonist Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acetylcholine Receptor (AChR) Antagonist Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acetylcholine Receptor (AChR) Antagonist drugs?
• How many Acetylcholine Receptor (AChR) Antagonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acetylcholine Receptor (AChR) Antagonist?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acetylcholine Receptor (AChR) Antagonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acetylcholine Receptor (AChR) Antagonist and their status?
• What are the key designations that have been granted to the emerging drugs?